



IN 2023, VETOQUINOL CELEBRATES ITS 90TH ANNIVERSARY Essential products for the most common needs

A strategy to meet the needs of its customers.

Vetoquinol is an independent, international animal health company that has made the strategic choice since 2012 to focus on global products that meet the main needs of its customers: veterinarians, breeders, and pet owners.

This focused strategy has resulted in a portfolio of "Essential" products. Vetoquinol's R&D and marketing efforts are mainly dedicated to the development of this portfolio through the launch of new products and the life cycle management of products already on the market.

What is an "Essential" product?

As the name suggests, it is a range of key products that meet the most common needs of the company's customers in the strategic countries where it operates. Vetoquinol offers veterinarians, breeders, and pet owners a comprehensive offer, including diagnostic aids, medicines and complementary services.

Launched in 2012, the development of the "Essentials" product portfolio includes, in 2023 around 50 products covering 3 species and 4 strategic segments in 24 countries. They represent more than 56% of the company's overall activity and are the driving force behind Vetoquinol's development dynamics.

Serving a "One health" approach

At least 60% of infectious human diseases, such as Covid-19, originate from animals. Health crises draws attention to the need for a "One Health" approach, which promotes an integrated, systemic and unified approach to human, animal and environmental health.

The well-being and health of humans and animals is at the core of Vetoquinol's business.

This is the raison d'être of the "Essentials" product portfolio, which covers most of the needs of veterinarians. These products have a proven or potential international outreach, and are leaders, or have the potential to become leaders, in their therapeutic areas, in which Vetoquinol has recognized expertise.

FOR MORE INFORMATION
CONTACT:

VETOQUINOL

Group Communications Officer

Resika Narain-Menigot

resika.narain-menigot@vetoquinol.com

KEIMA COMMUNICATION

Press Relations

Charles-Edouard Aubry

Tel.: +33 (0)6 09 09 48 32

charles-edouard.aubry@keima.fr

Investors Relations

Emmanuel Douergne

Tel.: +33 (0)6 76 94 40 87

emmanuel.douergne@keima.fr



Essential products in France

The Essential products portfolio is the most developed in France, the company's historical and original location. These Essential products are available in other European countries and other strategic territories through Marketing Authorizations obtained from local authorities such as the EMA in Europe or the FDA in the United States.

Vetoquinol products

In France, many Vetoquinol products are among the leaders in their markets, both among medicinal products (Tolfine®, Clavaseptin®, Drontal®, UpCard®, Propalin® and Profender®) and non-medicinal products (Flexadin®, Zylkène®, Sonotix® and Calf Lyte®). The recent launch of Felpreva® is an additional example of Vetoquinol's dynamism and development strategy.



ABOUT VETOQUINOL

Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the farm animals (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed more than 2,500 people as of December 31st, 2022.

Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO). The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.